IM
IMA.US ImageneBio, Inc.
- Market cap
- USD 43.2M
- P/E
- -
- P/B
- 0.34x
- ROE
- -37.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMA.US undervalued?
Graham numberThe Graham number of ImageneBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImageneBio, Inc. fundamental analysis
No fundamental analysis for ImageneBio, Inc. yet.
ImageneBio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July…
Full company profileImageneBio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ImageneBio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 990K | 13.8M | 9.19M | 31.0M | 15.6M | 9.16M | 3.50M | 800K | 0.00 |
| Gross Profit | -38.0M | -11.2M | -35.7M | -16.1M | -48.7M | 8.14M | 1.97M | -233K | - |
| Operating Income | -40.9M | -18.5M | -44.5M | -34.1M | -70.9M | -75.4M | -37.0M | -48.5M | -54.9M |
| EBITDA | -40.4M | -18.2M | -44.2M | -33.6M | -68.0M | -67.3M | -35.0M | -44.7M | -49.8M |
| Net Income | -40.9M | -16.8M | -44.3M | -34.1M | -68.8M | -68.2M | -36.6M | -45.3M | -48.6M |
| EPS | -14 | -5.63 | -15 | -11 | -23 | -20 | -31 | -8.35 | -2.84 |
| Balance Sheet | |||||||||
| Total Assets | 20.7M | 86.0M | 168M | 248M | 172M | 192M | 142M | 153M | 143M |
| Total Liabilities | 66.5M | 147M | 269M | 40.0M | 25.3M | 22.3M | 15.6M | 19.8M | 14.4M |
| Shareholders' Equity | -45.8M | -61.5M | -101M | 208M | 147M | 170M | 126M | 133M | 128M |
| Cash & Short-term Investments | 18.2M | 82.1M | 162M | 232M | 157M | 175M | 124M | 75.8M | 127M |
| Total Debt | 62.6M | 78.9M | 186K | 6.99M | 5.69M | 10.7M | 7.52M | 10.00M | 6.79M |
| Cash Flow | |||||||||
| Operating Cash Flow | -11.6M | 47.9M | -37.8M | -60.3M | -74.1M | -79.7M | -46.0M | -47.8M | -44.5M |
| Capital Expenditure | 305K | 316K | 766K | 1.76M | 1.43M | 414K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -11.9M | 47.6M | -38.6M | -62.0M | -75.5M | -80.2M | -46.0M | -47.8M | -44.5M |
| Ratios | |||||||||
| ROE | - | - | - | -16.4% | -46.8% | -40.2% | -29.0% | -34.1% | -37.9% |
| ROA | -197.6% | -19.6% | -26.3% | -13.8% | -39.9% | -35.5% | -25.8% | -29.6% | -34.1% |
| Net Profit Margin | -4,127.8% | -122.3% | -481.4% | -110.1% | -440.3% | -744.2% | -1,044.8% | -5,668.6% | - |
| Debt to Equity | - | - | - | 0.03x | 0.04x | 0.06x | 0.06x | 0.08x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ImageneBio, Inc. dividends
ImageneBio, Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:12 on Jul 28, 2025.
Who owns ImageneBio, Inc.
- Insiders 16.19%
- Institutions 54.48%
- Public & others 29.33%
- Shares outstanding 12.5M
- Free float 5.83M
Top funds holding IMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 265K | 2.13% | 0.00% | Sep 2026 |
| Worldwide Healthcare Ord | 136K | 1.09% | 0.00% | Jul 2026 |
| Fidelity Extended Market Index | 39.7K | 0.32% | +53.82% | Sep 2026 |
| iShares Micro-Cap ETF | 24.2K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 7.30K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 5.82K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.39K | 0.03% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 3.28K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.79K | 0.01% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 602.00 | 0.00% | 0.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 387.00 | 0.00% | -0.26% | Sep 2026 |
| Dimensional International Core Eq Acc | 236.00 | 0.00% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 194.00 | 0.00% | 0.00% | Sep 2026 |
| Global Core Equity UCITS ETF USD Acc | 152.00 | 0.00% | 0.00% | Oct 2026 |
| Guggenheim Active Allocation Fund | 26.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding IMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bvf Inc | 1.11M | 8.91% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 918K | 7.37% | -4.34% | Jun 2026 |
| Orbimed Advisors LLC | 909K | 7.30% | +140.19% | Jun 2026 |
| Cable Car Capital LLC | 782K | 6.27% | +3.56% | Jun 2026 |
| Omega Fund Management LLC | 455K | 3.66% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 334K | 2.69% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 321K | 2.57% | -1.43% | Jun 2026 |
| Trails Edge Capital Partners, LP | 282K | 2.26% | 0.00% | Jun 2026 |
| BML Capital Management LLC | 201K | 1.61% | 0.00% | Sep 2026 |
| Monashee Investment Management LLC | 192K | 1.54% | 0.00% | Jun 2026 |
| BlackRock Inc | 135K | 1.08% | +4.55% | Jun 2026 |
| Renaissance Technologies Corp | 78.5K | 0.63% | -9.70% | Sep 2026 |
| Adage Capital Partners Gp LLC | 66.7K | 0.54% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 55.6K | 0.45% | -55.28% | Jun 2026 |
| Geode Capital Management, LLC | 53.5K | 0.43% | -10.71% | Jun 2026 |
| NEA Management Company, LLC | 50.0K | 0.40% | 0.00% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 50.0K | 0.40% | +66.67% | Jun 2026 |
| HSBC Holdings PLC | 34.2K | 0.27% | -1.88% | Jun 2026 |
| Sofinnova Ventures | 31.9K | 0.26% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 27.5K | 0.22% | +0.69% | Jun 2026 |
ImageneBio, Inc. company profile
- Company name
- ImageneBio, Inc.
- Ticker
- IMA.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- 12526 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858 345 6265
- Website
- inmagenebio.com
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc. management
5- Dr. Kristin Yarema Ph.D.CEO & Director · born 1971
- Ms. Yanina Grant-HuertaCFO, Principal Financial Officer & Principal Accounting Officer · born 1977
- Dr. Kurinji Pandiyan Ph.D.Chief Strategy & Operations Officer
- Ms. Renuka Sivendran Ph.D.Chief Technical Officer
- Mr. Matt Robbins J.D.General Counsel